Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You (or a family member, spouse, or legal guardian acting on your behalf) are able to understand what this study involves and are willing to sign a consent form allowing your health information to be used.
- You are at least 18 years old at the time you sign the consent form.
- You have been diagnosed with mild cognitive impairment (MCI) or dementia that doctors suspect may be related to Alzheimer's disease, and you are either being considered for treatment, about to start treatment, or have already started a newly FDA-approved Alzheimer's treatment in your regular medical care.
- If you are starting treatment at the same time as joining this study, your treatment follows the official guidelines and requirements for the FDA-approved Alzheimer's medication you are receiving.
- Your doctor has already decided to offer you care or treatment based on your medical needs, completely separate from and before this study.
Who may not be able to join:
- There are no exclusion criteria listed in the official study information provided (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gil Rabinovici, MD, University of California, San Francisco
Phone: 215-574-3181
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate whether FDA-approved treatments improve health outcomes (as measured by slowing of cognitive decline) over time in a real-world population in broad clinical settings.; Evaluate whether FDA-approved treatments improve health outcomes (as measured by slowing of cognitive decline) over time in a real-world population in broad clinical settings.; Evaluate whether FDA-approved treatments improve health outcomes (as measured by slowing of functional decline) over time in a real-world population in broad clinical settings.; Evaluate safety outcomes of FDA-approved treatments over time in a r...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.